Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2026, it ...

Net sales rose 3% in dollars to $14.4 billion, beating estimates, while core operating profit held flat at $5.94 billion ...

Novartis said it returned to sales growth in the second quarter, as momentum from some of its key medicines and recent launches helped the company offset a hit from drugs that lost patent protection.

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Novartis said it returned to sales growth for the second quarter, after lower-priced competition in the U.S. for drugs that went off patent weighed on its top and bottom lines in prior quarters. Net ...

Analysts expect Novartis to make a core operating profit of $5.31 billion for the quarter, according to the same consensus. The company made $5.925 billion f ...

Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.

Swiss pharma giant Novartis AG NVS reported second-quarter core earnings per share (excluding one-time charges) of $2.41, ...

Despite generic competition, Novartis returned to a growth trajectory in the second quarter. Management has confirmed its ...

Novartis NVS recently announced positive final results from the late-stage, APPLAUSE-IgAN, study on Fabhalta (iptacopan) in adults living with IgA nephropathy (IgAN), a progressive autoimmune kidney ...